(Q41366537)

30 September 2017

Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States (English)

1 reference

30 September 2017

0 references

1 reference

ChEBI release 2020-05-28

1 reference

4

Maria Stepanova

1 reference

30 September 2017

Zobair M Younossi

1

1 reference

30 September 2017

Yushan Jiang

series ordinal

2

1 reference

30 September 2017

Nathaniel J Smith

series ordinal

3

1 reference

30 September 2017

Rachel Beckerman

series ordinal

5

1 reference

30 September 2017

language of work or name

English

0 references

publication date

23 March 2015

1 reference

30 September 2017

1 reference

30 September 2017

61

1 reference

30 September 2017

5

1 reference

30 September 2017

1471-1478

1 reference

Hepatitis C and work impairment: a review of current literature

30 September 2017

1 reference

Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection

21 January 2018

1 reference

Economic burden associated with patients diagnosed with hepatitis C.

21 January 2018

1 reference

National estimates of healthcare utilization by individuals with hepatitis C virus infection in the United States

21 January 2018

1 reference

Humanistic and economic impacts of hepatitis C infection in the United States

21 January 2018

1 reference

The burden of untreated hepatitis C virus infection: a US patients' perspective

21 January 2018

1 reference

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

21 January 2018

1 reference

Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma

21 January 2018

1 reference

Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease

21 January 2018

1 reference

Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C.

21 January 2018

1 reference

Distribution of hepatitis C virus genotypes in a diverse US integrated health care population

21 January 2018

1 reference

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy

21 January 2018

1 reference

Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers

21 January 2018

1 reference

Health and productivity as a business strategy

21 January 2018

1 reference

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

21 January 2018

1 reference

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

21 January 2018

1 reference

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

21 January 2018

1 reference

Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study

21 January 2018

1 reference

A review of health-related workplace productivity loss instruments

21 January 2018

1 reference

Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens

21 January 2018

1 reference

Hepatitis a epidemiology goes global

21 January 2018

1 reference

The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities

21 January 2018

1 reference

Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study.

21 January 2018

1 reference

The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity

21 January 2018

1 reference

Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment

21 January 2018

1 reference

Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients

21 January 2018

1 reference

Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C.

21 January 2018

1 reference

Effect of orthotopic liver transplantation on employment and health status

21 January 2018

1 reference

Employment and health insurance in long-term liver transplant recipients

21 January 2018

1 reference

Employment and quality of life in liver transplant recipients

21 January 2018

1 reference

The changing burden of hepatitis C virus infection in the United States: model-based predictions.

21 January 2018

1 reference

All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

The validity and reproducibility of a work productivity and activity impairment instrument

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Predictors of employment after liver transplantation

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/HEP.27757

1 reference

30 September 2017

1 reference